Liu Guihong, Hu Binbin, Chen Tao, Zhang Xin, Tang Yu, Chen Qian, Shi Huashan
Department of Biotherapy, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Department of Cardiology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China.
Front Oncol. 2024 Mar 6;14:1310073. doi: 10.3389/fonc.2024.1310073. eCollection 2024.
About 40% of esophageal squamous cell carcinoma (ESCC) patients experienced recurrence after neoadjuvant chemoradiotherapy (nCRT) plus esophagectomy. While limited information was available on recurrence risk stratification in ESCC after neoadjuvant treatment. Our previous study showed ypN status was a reliable tool to differentiate and predict the prognosis in the recurrent population. Here, we evaluated recurrence timing and patterns in ESCC patients, taking into consideration lymph node status after nCRT.
A total of 309 ESCC patients treated with nCRT plus esophagectomy between 2018 and 2021 were enrolled in this observational cohort study. Lymph node status was recorded by the pathologist according to the surgical specimens. We retrospectively investigated the timing and patterns of recurrence and the prognoses in ESCC patients, taking into consideration lymph node status after nCRT.
After nCRT plus surgery in ESCC patients, lymph node metastasis was associated with unfavorable clinicopathological factors and high risks of recurrence. In the recurrent subgroup, ypN+ patients experienced earlier recurrence, especially for locoregional recurrence within the first year. Moreover, ypN+ patients had poorer prognosis. However, the recurrence patterns in the ypN- and ypN+ groups were similar. Besides, there were no significant differences in surgery to recurrence, recurrence to death, or overall survival among patients with locoregional or distant recurrence for overall patients and within ypN- or ypN+ groups.
Lymph node metastasis was correlated with unfavorable clinicopathological factors and high risks of recurrence. Despite a similar recurrence pattern in the recurrent subgroup between the ypN- and ypN+ groups, ypN+ patients exhibited earlier recurrence and a worse prognosis.
约40%的食管鳞状细胞癌(ESCC)患者在新辅助放化疗(nCRT)加食管切除术后出现复发。然而,关于新辅助治疗后ESCC复发风险分层的信息有限。我们之前的研究表明,ypN状态是区分和预测复发人群预后的可靠工具。在此,我们评估了ESCC患者的复发时间和模式,并考虑了nCRT后的淋巴结状态。
本观察性队列研究纳入了2018年至2021年间接受nCRT加食管切除术治疗的309例ESCC患者。病理学家根据手术标本记录淋巴结状态。我们回顾性研究了ESCC患者的复发时间和模式以及预后情况,并考虑了nCRT后的淋巴结状态。
ESCC患者接受nCRT加手术后,淋巴结转移与不良的临床病理因素及高复发风险相关。在复发亚组中,ypN+患者复发较早,尤其是在第一年出现局部区域复发。此外,ypN+患者预后较差。然而,ypN-组和ypN+组的复发模式相似。此外,总体患者以及ypN-组或ypN+组内,局部区域复发或远处复发患者在手术至复发、复发至死亡或总生存方面均无显著差异。
淋巴结转移与不良的临床病理因素及高复发风险相关。尽管ypN-组和ypN+组复发亚组的复发模式相似,但ypN+患者复发较早且预后较差。